Warning: mail() has been disabled for security reasons in /home/markrref/public_html/usmarketbuzz.com/wp-content/mu-plugins/bps-mu-tools.php on line 110

Warning: Cannot modify header information - headers already sent by (output started at /home/markrref/public_html/usmarketbuzz.com/wp-content/mu-plugins/bps-mu-tools.php:110) in /home/markrref/public_html/usmarketbuzz.com/wp-content/plugins/bigcontact/BigContact.php on line 43

Warning: Cannot modify header information - headers already sent by (output started at /home/markrref/public_html/usmarketbuzz.com/wp-content/mu-plugins/bps-mu-tools.php:110) in /home/markrref/public_html/usmarketbuzz.com/wp-includes/feed-rss2.php on line 8
OTCBB:GEQU – US Market Buzz http://www.usmarketbuzz.com Nation and Economy Mon, 20 Jul 2020 16:28:22 +0000 en-US hourly 1 https://wordpress.org/?v=4.9.23 Are You Investing Into The Biotech Dip? CASI Pharmaceuticals Inc (NASDAQ:CASI), Global Equity International Inc (OTCBB:GEQU), SCIVAC THERAPEUTICS INC (OTCMKTS:SVACF) http://www.usmarketbuzz.com/are-you-investing-into-the-biotech-dip-casi-pharmaceuticals-inc-nasdaqcasi-global-equity-international-inc-otcbbgequ-scivac-therapeutics-inc-otcmktssvacf-3297 Thu, 15 Oct 2015 12:50:02 +0000 http://www.usmarketbuzz.com/?p=3297 On Wednesday Richmond Federal Reserve President Jeffrey Lacker stated a brief occurrence of upsetting economic information that has done little to alter his outlook for the U.S economy. Lacker, who voted for an interest rate increase in September against the majority of Fed policymakers who choose to keep rates steady, stated he has not decided on how he will vote at the Oct. 27th-28th meeting. Although he was not persuade much by a slowdown in job growth and weaker-than-expected retail sales in September. “It doesn’t change my outlook much,” he told Fox Business in an interview hopefully his stance doesn’t impact the value of biotech stock such as:

CASI Pharmaceuticals Inc (NASDAQ:CASI) is a public, biopharma company dedicated to certain therapeutics that focus on cancer and other unmet medical needs. In a recent announcement CASI Pharmaceuticals Inc (NASDAQ:CASI) revealed that its oncology drug candidate, ENMD-2076 received Orphan Drug designation from the European Medicines Agency for the treatment of hepatocellular carcinoma (HCC), including fibrolamellar carcinoma, a rare type of HCC. In the past 30 days beginning on September 15 to October 14th CASI has seen a large increase in price of 78.43%. This new designation gives CASI 10 years of market exclusivity in EU after ENMD-2076 receives marketing authorization there. The product was previously granted Orphan Drug designation for the treatment of HCC by US Food and Drug Administration last year and provides CASI with a 7-year market exclusivity in the country after its New Drug Application approval.

Why Are Investors Scrambling For Shares Of THIS Biotechnology Stock?

Global Equity International Inc (OTCBB:GEQU) through its wholly-owned subsidiary Global Equity Partners Plc., advises worldwide business leaders with their most crucial decisions and opportunities dealing with growth, capital needs, structure and the development of a global presence. With locations in Dubai and London, Global Equity has built a strong relationships in the US, UK, Central Europe, the Middle East and South East Asia to help clients in realizing their full value and potential by bringing them to external capital and resources that place an emphasis on collaborative thinking. Global Equity International Inc (OTCBB:GEQU) Is very pleased to release the news about a strategic partnership agreement with the “Middle East Prospect Exhibition” (“MEPEX” -www.mepexonline.com), to work as their exclusive selected Financial Partner for capital raising, Advisory and Public Listings for all of the MEPEX participants. GEQU has seen a major price increase in the past 3 months of 1022.73% making them a penny stock to watch for shareholders invested in the biotech sector.

WHAT BIOTECH STOCK ARE STREET ANALYSTS CALLING “THE NEXT WINNING STOCK”?

SCIVAC THERAPEUTICS INC (OTCMKTS:SVACF) Who’s headquarters are located in Rehovot Israel, is in the business of developing, manufacturing and promoting biological products for human healthcare. The Company’s flagship product, Sci‐B‐Vac™, is a recombinant 3rd generation hepatitis B vaccine. SCIVAC THERAPEUTICS INC (OTCMKTS:SVACF) announced that its wholly-owned subsidiary SciVac Ltd. has obtained the go-ahead from the Israeli Ministry of Health to progress further on all standard manufacturing,involving labeling and release of Sci-B-Vac(TM) to the market, following corrective actions to the automated labeling system and a overview of the Company’s facilities earlier in the month of September. SVACF is up from last Friday’s close increasing 13% following highs of $0.0195 on Tuesday. In past announcements, it was noted that Opko Health, Inc. (OPKO) had a 45% stake in SciVac. Sci-B-Vac has displaying a performance in 20+ company-sponsored or investigator- initiated trials, dealing with more than 5000 who have enrolled while also being administered to over 500,000 patients to date, with favorable safety and efficacy profiles according to company data.

]]> U.S. Jobs Report Has Not Affected These Stocks: Holiday Island Holdings Inc (OTCMKTS:HIHI), Sierra Resource Group Inc (OTCMKTS:SIRG), Global Equity International Inc (OTCBB:GEQU), Cell MedX Corp (OTCBB:CMXC) http://www.usmarketbuzz.com/u-s-jobs-report-has-not-affected-these-stocks-holiday-island-holdings-inc-otcmktshihi-sierra-resource-group-inc-otcmktssirg-global-equity-international-inc-otcbbgequ-cell-medx-corp-otcb-3221 Fri, 04 Sep 2015 20:39:32 +0000 http://www.usmarketbuzz.com/?p=3221 If you haven’t heard, the US August Jobs numbers came in and if ever there was a shortfall, it was recognizable today. Expectations on the street were in the ball-park of 220,000 non farm jobs but when the raw data came in, the report showed a deficit of more than 40,000 jobs. The August numbers came in around 173,000 new jobs created during the month. Unfortunately for large cap stocks, this did not bode well. Johnson & Johnson (NYSE:JNJ), Microsoft Corporation (NASDAQ:MSFT), and even Netflix, Inc. (NASDAQ:NFLX) fell by more than 2% by the time the lunch hour rolled in on Friday. As of 11:30AM EST the Nasdaq, S&P 500, and DJIA all showed negative price movement.

Despite these losses and the drop in U.S. jobs numbers, traders have found opportunity in higher volatile markets like that of forex, futures as well as penny stocks. Holiday Island Holdings Inc (OTCMKTS:HIHI), Sierra Resource Group Inc (OTCMKTS:SIRG), Global Equity International Inc (OTCBB:GEQU), and Cell MedX Corp (OTCBB:CMXC)

Holiday Island Holdings, Inc. an emerging small cap company, is currently making progress to acquire particular income producing commercial and residential properties located in Arkansas. The company’s most recent press release announcing that the company is in the works talking with a large Kansas- based developer on the shopping center funding valued at $10,000,000. Over the last month HIHI has seen a price increase of 400% from lows of $0.0001 to highs of $0.0005. On Friday HIHI jumped 100% from an opening price of $0.0002 to a days high of $0.0004.

Sierra Resource Group Inc. a company that engages in the exploration, discovery, and development of mineral resource properties has seen continued momentum over the last couple of weeks. Increased trading volume has seen to be the driving force for the stock’s 1550% over the last month. SIRG has seen lows of $0.0006 back in early August to highs of $0.0099. The stock is currently trading between $0.0016-$0.0019 as of Friday.

Global Equity International, Inc. and its fully owned subsidiary Global Equity Partners Plc., a specialist consultancy firm announced on Friday the company will reapply for OTCQB listing status, once the Company’s closing bid builds at $0.01 or higher. Prior to the most recent press release the company also announced they have signed a consulting agreement with Advanced Imaging Projects. The CEO stated, “AIP has a unique and specialist business that we find very interesting. They have thought through their business model in fine detail and represent a company built on solid plans and aspirations. We will, over time, seek to help AIP establish their products in the Middle Eastern market from Dubai, which offers a huge potential customer base, coupled with ruling family decree to build on their current healthcare facilities. We believe AIP will become one of the market leaders in its sector in a very short space of time and look forward to the long and prosperous journey ahead we are all embarking on.” GEQU over the last 60 days has seen price per share spike of 850% from lows back in July of $0.0014 to highs on Friday of $0.0133.

Cell MedX Corp. a development stage company focused on the discovery, development and commercialization of therapeutic devices for patients with diabetes has seen an increase in trading activity this past week. The company is looking to take a different approach to diabetes treatment that could essentially innovate a new category in the space. Last year, the company bought the rights to a proprietary micro current technology called eBalance that will improve diabetic metabolic markers and lessen the need for insulin, while helping the long-term prognosis for the rising number afflicted with the condition. CMXC over the last 30 days has seen a hike of 126% from lows of $0.15 to highs of $0.34. The stock is currently seeing trading levels between $0.18-$0.21.

]]>